Zosano Pharma Corporation (ZSANQ) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Zosano Pharma Corporation (ZSANQ) trades at $0.0002. Zosano Pharma Corporation is a clinical-stage biopharmaceutical company focused on migraine therapeutics using a transdermal microneedle system. The company filed for Chapter 11 bankruptcy in 2022. Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 18, 2026Analyst Coverage for ZSANQ: ZSANQ does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates ZSANQ against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
Not enough scored data yet to form a council read on ZSANQ.
How is this calculated? →Zosano Pharma Corporation (ZSANQ) Healthcare & Pipeline Overview
Zosano Pharma Corporation, a clinical-stage biopharmaceutical company specializing in migraine treatments via its microneedle technology, filed for Chapter 11 bankruptcy in 2022. Its lead product, Qtrypta, aimed to deliver zolmitriptan transdermally, but the company now faces significant financial and operational challenges within the competitive biotechnology sector.
What Is the Investment Thesis for ZSANQ?
Zosano Pharma Corporation's Chapter 11 bankruptcy filing in June 2022 presents a highly speculative investment scenario. The company's negative profit margin of -3836.2% and gross margin of -1.4% indicate severe financial difficulties. While its Qtrypta product held potential in the migraine treatment market, the bankruptcy proceedings raise substantial doubts about its ability to continue operations or commercialize its product. The high beta of 3.08 suggests significant volatility. Any investment would depend on the outcome of the bankruptcy proceedings and potential restructuring plans, which are highly uncertain as of March 18, 2026.
Based on FMP financials and quantitative analysis
ZSANQ Key Highlights
Chapter 11 Filing: Zosano Pharma filed for Chapter 11 bankruptcy on June 1, 2022, indicating significant financial distress.
- Negative Profit Margin: The company's profit margin is -3836.2%, reflecting substantial losses.
- Negative Gross Margin: Zosano's gross margin is -1.4%, indicating that the cost of goods sold exceeds revenue.
- Lead Product: Qtrypta (M207) was the company's lead product candidate for the acute treatment of migraine.
- Microneedle Technology: Zosano utilized a transdermal microneedle system for drug delivery.
Who Are ZSANQ's Competitors?
ZSANQ is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| VRTX Vertex Pharmaceuticals Incorporated | $540.26 | -2.14% | $137B | 98 |
| REGN Regeneron Pharmaceuticals, Inc. | $835.15 | -0.68% | $86.0B | 94 |
| ALNY Alnylam Pharmaceuticals, Inc. | $229.30 | -5.49% | $30.7B | 92 |
| RPRX Royalty Pharma plc | $60.58 | -1.86% | $26.9B | 75 |
| INCY Incyte Corporation | $127.80 | -0.53% | $25.9B | 99 |
| UTHR United Therapeutics Corporation | $520.23 | -1.68% | $22.1B | 98 |
| NBIX Neurocrine Biosciences, Inc. | $153.42 | -1.37% | $15.4B | 93 |
| EXEL Exelixis, Inc. | $53.69 | -1.29% | $13.5B | 98 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ZSANQ's Key Strengths?
Proprietary transdermal microneedle technology
- Potential for faster drug delivery
- Targeted migraine treatment market
What Are ZSANQ's Weaknesses?
Chapter 11 bankruptcy filing
- Negative profit and gross margins
- Limited financial resources
What Could Drive ZSANQ Stock Higher?
Bankruptcy proceedings and potential restructuring plans.
- Potential acquisition by another pharmaceutical company (timeline uncertain).
- Potential partnership for Qtrypta development (timeline uncertain).
What Are the Key Risks for ZSANQ?
Negative return on equity (-74.8%) — the business is not currently generating profit on shareholder capital.
- Chapter 11 bankruptcy and potential liquidation.
- Failure to secure funding or partnerships.
- Regulatory hurdles and clinical trial setbacks.
- Limited financial resources and negative profit margins.
What Are the Growth Opportunities for ZSANQ?
- Restructuring and Acquisition: A potential growth opportunity lies in a successful restructuring of the company under Chapter 11, possibly leading to an acquisition by a larger pharmaceutical company. This would require a viable plan to address the company's debt and demonstrate the value of its Qtrypta product and microneedle technology. The timeline for such a scenario is highly uncertain, depending on the bankruptcy proceedings.
- Partnership for Qtrypta: Zosano could seek a partnership with another pharmaceutical company to continue the development and commercialization of Qtrypta. This would require demonstrating the clinical efficacy and market potential of the product to attract a suitable partner. The timeline for securing a partnership is uncertain and contingent on the company's financial stability and the attractiveness of Qtrypta.
- Microneedle Technology Licensing: Zosano's transdermal microneedle technology could be licensed to other companies for use in different therapeutic areas. This would provide a revenue stream and potentially revive the company's prospects. The market for microneedle drug delivery systems is growing, but competition is also increasing.
- Sale of Assets: The company could sell its assets, including its intellectual property and manufacturing facilities, to raise capital and pay off debts. This would provide a short-term solution to the company's financial problems, but it would also mean the end of Zosano as an independent entity. The timeline for asset sales depends on the bankruptcy proceedings and the availability of buyers.
- New Therapeutic Applications: Exploring new therapeutic applications for its microneedle technology beyond migraine treatment could open new growth avenues. This would require significant investment in research and development and could take several years to yield results. The potential market size would depend on the specific therapeutic areas targeted.
What Threats Does ZSANQ Face?
- Competition from established pharmaceutical companies
- Regulatory hurdles and clinical trial risks
- Uncertainty surrounding bankruptcy proceedings
What Are ZSANQ's Competitive Advantages?
- Proprietary transdermal microneedle technology.
- Patent protection for Qtrypta formulation.
- Potential for faster drug delivery and improved patient compliance.
What Does ZSANQ Do?
Founded in 2006 and headquartered in Fremont, California, Zosano Pharma Corporation was a clinical-stage biopharmaceutical company dedicated to developing and commercializing therapeutics for migraine using its innovative transdermal microneedle system. The company's primary focus was on its lead product candidate, Qtrypta (M207), a proprietary formulation of zolmitriptan designed for the acute treatment of migraine. Qtrypta aimed to offer a faster and more convenient delivery method compared to traditional oral medications. Zosano's microneedle technology was intended to improve drug absorption and patient compliance. However, on June 1, 2022, Zosano Pharma Corporation filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware, signaling significant financial distress and casting doubt on the future of its operations and product pipeline. The company's evolution from a promising biotech startup to a bankrupt entity highlights the challenges inherent in the pharmaceutical industry, including regulatory hurdles, clinical trial risks, and the need for substantial capital investment.
What Products and Services Does ZSANQ Offer?
- Developed a transdermal microneedle system for drug delivery.
- Focused on therapeutics for migraine treatment.
- Developed Qtrypta (M207), a zolmitriptan formulation for acute migraine treatment.
- Aimed to provide a faster and more convenient drug delivery method.
- Sought to improve drug absorption and patient compliance.
- Filed for Chapter 11 bankruptcy in 2022.
How Does ZSANQ Make Money?
- Focused on developing and commercializing pharmaceutical products.
- Utilized a proprietary transdermal microneedle technology.
- Aimed to generate revenue through product sales and licensing agreements.
What Industry Does ZSANQ Operate In?
Zosano Pharma Corporation operated within the competitive biotechnology industry, which is characterized by high research and development costs, lengthy regulatory approval processes, and significant clinical trial risks. The migraine treatment market is substantial, with a growing demand for more effective and convenient therapies. However, Zosano's bankruptcy reflects the challenges faced by smaller biotech companies in securing funding and navigating the complexities of drug development and commercialization. Competitors like ALNAQ and ARTH are also operating in this space.
Who Are ZSANQ's Key Customers?
- Migraine sufferers seeking acute treatment.
- Healthcare providers prescribing migraine medication.
- Potential pharmaceutical partners for product development and commercialization.
Company Profile
Zosano Pharma Corporation operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Fremont, US. The company is led by CEO Steven Lo.
Key Financial Metrics
Return on equity for Zosano Pharma Corporation stands at -74.8%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -62.2%, showing how much profit it generates from its asset base. A current ratio of 1.04 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -48.2%, the inverse of the P/E and a quick read on earnings relative to price.
ZSANQ Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Proprietary transdermal microneedle technology
- Potential for faster drug delivery
- Targeted migraine treatment market
- Ongoing: Bankruptcy proceedings and potential restructuring plans.
Bear Case
- Chapter 11 bankruptcy filing
- Negative profit and gross margins
- Limited financial resources
- Ongoing: Chapter 11 bankruptcy and potential liquidation.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
ZSANQ Latest News
No recent news available for ZSANQ.
ZSANQ Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ZSANQ.
Price Targets
Wall Street price target analysis for ZSANQ.
ZSANQ MoonshotScore
What does this score mean?
The MoonshotScore rates ZSANQ 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Steven Lo
CEO
Steven Lo served as the CEO of Zosano Pharma Corporation, managing a team of 40 employees. Information on his prior experience and educational background is not available in the provided data. As CEO, he was responsible for overseeing the company's strategic direction, operations, and financial performance.
Track Record: Under Steven Lo's leadership, Zosano Pharma focused on developing and commercializing its Qtrypta product. However, the company ultimately filed for Chapter 11 bankruptcy in 2022, indicating significant challenges in achieving its strategic goals. His tenure was marked by the company's efforts to navigate the competitive pharmaceutical landscape and secure funding for its research and development programs.
ZSANQ OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Zosano Pharma Corporation (ZSANQ) does not meet the minimum financial standards or reporting requirements for the higher tiers (OTCQX and OTCQB). Companies in this tier may be distressed, have limited operating history, or choose not to comply with stricter listing standards. Investing in OTC Other stocks carries significant risks due to the lack of regulatory oversight and transparency compared to NYSE or NASDAQ-listed companies.
- OTC Tier: OTC Other
- Limited financial disclosure and transparency
- Low trading volume and liquidity
- Potential for price manipulation
- Higher risk of fraud or mismanagement
- Uncertainty surrounding bankruptcy proceedings
- Verify the company's current legal status and compliance with OTC regulations.
- Review any available financial statements and assess the company's financial health.
- Research the background and experience of the company's management team.
- Understand the company's business model and competitive landscape.
- Assess the potential risks and uncertainties associated with the company's bankruptcy proceedings.
- Monitor news and filings related to the company's restructuring efforts.
- Consult with a financial advisor before making any investment decisions.
- Established history as a clinical-stage biopharmaceutical company.
- Development of a proprietary transdermal microneedle technology.
- Focus on migraine treatment with Qtrypta product candidate.
Zosano Pharma Corporation Healthcare Stock: Key Questions Answered
What does Zosano Pharma Corporation do?
Zosano Pharma Corporation was a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for migraine using its proprietary transdermal microneedle system. Its lead product candidate, Qtrypta (M207), was a formulation of zolmitriptan designed for the acute treatment of migraine.
What do analysts say about ZSANQ stock?
Given Zosano Pharma Corporation's Chapter 11 bankruptcy filing, formal analyst coverage is likely limited or non-existent as of March 18, 2026. Key valuation metrics such as price targets and ratings are unlikely to be available due to the company's financial distress and uncertain future. Any potential investment should be approached with extreme caution, considering the high risk associated with bankrupt companies and the lack of analyst consensus.
What are the main risks for ZSANQ?
The primary risk for ZSANQ is the ongoing Chapter 11 bankruptcy proceedings, which could result in liquidation of the company's assets and a complete loss of investment for shareholders. Additional risks include the company's limited financial resources, negative profit margins, and the uncertainty surrounding its ability to restructure or secure funding. The company also faces regulatory hurdles and clinical trial risks associated with its pharmaceutical product development efforts.
What are the key factors to evaluate for ZSANQ?
Evaluate ZSANQ on fundamentals, analyst consensus, and risk factors. Zosano Pharma Corporation's Chapter 11 bankruptcy filing in June 2022 presents a highly speculative investment scenario. Not financial advice.
How frequently does ZSANQ data refresh on this page?
ZSANQ's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven ZSANQ's recent stock price performance?
Zosano Pharma Corporation (ZSANQ) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary transdermal microneedle technology. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ZSANQ overvalued or undervalued right now?
Zosano Pharma Corporation (ZSANQ) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research ZSANQ before investing?
Before investing in Zosano Pharma Corporation (ZSANQ), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be incomplete due to the company's bankruptcy status.
- The OTC market carries inherent risks due to limited regulation and transparency.